BZW2 promotes malignant progression in lung adenocarcinoma through enhancing the ubiquitination and degradation of GSK3β
Article in Cell Death Discovery (February 2024)
The most recent citing publications are shown below. View all 22 publications that cite this research output on Dimensions.
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Article in Clinical Cancer Research (November 2023)
The Role of Nrf2 Activation and Autophagy in Aging and Neurodegenerative Diseases
Book chapter (March 2023)